Paper Details

  1. Home
  2. Paper Details

Ivermectin in COVID-19: The Case for a Moratorium on Prescriptions.

Author: AlterScott M, BergesMaja, ClaytonLisa M, DeMetsDavid L, HennekensCharles H, LauStephanie, MakiDennis G, MasaRaymond B, MolnarAndreea, ShihRichard D, SolanoJoshua J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Ivermectin, an antiparasitic drug, is not FDA-approved for the treatment or prevention of COVID-19. Despite this, ivermectin prescriptions in the US have increased significantly. While some basic research suggests potential benefits, reliable data from large randomized trials is lacking. The FDA, NIH, WHO, and EMA all advise against using ivermectin for COVID-19 outside of clinical trials.
Paper Details　
Original Abstract of the Article :
In treatment or prevention of COVID-19, ivermectin is not approved by the United States (US) Food and Drug Administration (FDA). Nonetheless, in the US, prescriptions of ivermectin by healthcare providers have increased > tenfold from 3589 per week pre-COVID-19 to 39,102. Ivermectin is FDA approved ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086156/

データ提供：米国国立医学図書館（NLM）

Ivermectin for COVID-19: Navigating the Desert of Unproven Treatments

The COVID-19 pandemic, like a vast desert, has presented numerous challenges, with researchers searching for effective treatments and preventive measures. Ivermectin, a drug commonly used for parasitic infections, has emerged as a potential treatment for COVID-19, but its effectiveness remains uncertain. This commentary, published in the American Journal of Tropical Medicine and Hygiene, urges caution in prescribing ivermectin for COVID-19, highlighting the need for rigorous scientific evidence.

The Mirage of Ivermectin: A Cautionary Tale in the Desert of COVID-19

The commentary emphasizes the lack of robust scientific evidence supporting the use of ivermectin for COVID-19 treatment or prevention. It's like a mirage in the desert, appearing promising but ultimately leading to disappointment. The authors argue that prescribing ivermectin for COVID-19 outside of carefully controlled clinical trials is premature and potentially risky.

Navigating the Desert of COVID-19: Seeking Evidence-Based Treatments

This commentary underscores the importance of relying on sound scientific evidence when choosing treatments for COVID-19. It's like navigating a desert, where reliable sources of information are essential for survival. The authors urge healthcare providers to prioritize evidence-based therapies and discourage the use of unproven medications like ivermectin for COVID-19.

Dr. Camel's Conclusion

This commentary serves as a timely reminder in the desert of COVID-19. It emphasizes the importance of relying on evidence-based treatments, avoiding the allure of unproven remedies. It's like finding a reliable compass in the desert, guiding us towards safe and effective treatment options.
Date :
  1. Date Completed 2022-04-04
  2. Date Revised 2023-11-05
Further Info :

Pubmed ID

35147927

DOI: Digital Object Identifier

PMC9086156

Related Literature

Article Analysis
・Side Effects of ivermectin topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.